Anna M May1, Lu Wang2, Kingman P Strohl1, Harneet Walia3, Stan L Hazen4,5, Reena Mehra3. 1. Division of Pulmonary, Critical Care, and Sleep Medicine, VA Northeast Ohio Healthcare System, Cleveland, Ohio; and. 2. Department of Quantitative Health Sciences, Lerner Research Institute. 3. Sleep Disorders Center, Neurologic Institute, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University. 4. Department of Cellular and Molecular Medicine, Lerner Research Institute, and. 5. Department of Cardiovascular Disease, Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
Abstract
Rationale: Knowledge of sex-specific changes of cardiovascular biomarkers in response to continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea (OSA) is limited. Objectives: We hypothesized a differential sex-specific cardiovascular biomarker response with CPAP therapy for OSA. Methods:Participants with moderate-severe OSA (apnea-hypopnea index, 15 events/h) were randomized to CPAP versus sham and completed polysomnography and collection of biomarkers of inflammation (myeloperoxidase, fibrinogen, paraoxonase, interleukin [IL]-6, IL-6 soluble receptor, aryl esterase, oxidized low-density lipoprotein, lipoprotein A, plasminogen activator inhibitor 1, and F2-isoprostane urine/creatinine ratio) and vascular measures at baseline and 8 weeks of therapy with either CPAP (n = 72) or sham treatment (n = 70). Post hoc secondary analyses of sex-study arm interaction relative to change in inflammatory biomarkers were evaluated via linear regression with adjustment for baseline biomarker value, age, race, body mass, index, waist circumference, and CPAP adherence. Interactions were further evaluated via sex-stratified analyses. Results: The study sample comprised a total of 149 participants aged 50.8 ± 11.7 years; 55% were male, and 55% were white. Participants had a median apnea-hypopnea index of 26.3 events per hour (interquartile range, 13-37). There were substantial interactions between study arm and sex for myeloperoxidase, paraoxonase, and fibrinogen (P = 0.03, P = 0.03, and P = 0.08, respectively). No significant interactions were found for the vascular measures. Estimates were similar but with decreased power in sex-stratified analyses, with decreased biomarkers in women and increased biomarkers in men.Conclusions: Differential sex-specific responses to CPAP therapy for OSA were observed for circulating inflammatory biomarkers, which persisted after adjustment for confounders. These findings set the stage for validation studies and, if confirmed, biochemical pathway elucidation to inform sex-specific personalized treatment approaches.Clinical trial registered with www.clinicaltrials.gov (NCT00607893).
RCT Entities:
Rationale: Knowledge of sex-specific changes of cardiovascular biomarkers in response to continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea (OSA) is limited. Objectives: We hypothesized a differential sex-specific cardiovascular biomarker response with CPAP therapy for OSA. Methods:Participants with moderate-severe OSA (apnea-hypopnea index, 15 events/h) were randomized to CPAP versus sham and completed polysomnography and collection of biomarkers of inflammation (myeloperoxidase, fibrinogen, paraoxonase, interleukin [IL]-6, IL-6 soluble receptor, aryl esterase, oxidized low-density lipoprotein, lipoprotein A, plasminogen activator inhibitor 1, and F2-isoprostane urine/creatinine ratio) and vascular measures at baseline and 8 weeks of therapy with either CPAP (n = 72) or sham treatment (n = 70). Post hoc secondary analyses of sex-study arm interaction relative to change in inflammatory biomarkers were evaluated via linear regression with adjustment for baseline biomarker value, age, race, body mass, index, waist circumference, and CPAP adherence. Interactions were further evaluated via sex-stratified analyses. Results: The study sample comprised a total of 149 participants aged 50.8 ± 11.7 years; 55% were male, and 55% were white. Participants had a median apnea-hypopnea index of 26.3 events per hour (interquartile range, 13-37). There were substantial interactions between study arm and sex for myeloperoxidase, paraoxonase, and fibrinogen (P = 0.03, P = 0.03, and P = 0.08, respectively). No significant interactions were found for the vascular measures. Estimates were similar but with decreased power in sex-stratified analyses, with decreased biomarkers in women and increased biomarkers in men.Conclusions: Differential sex-specific responses to CPAP therapy for OSA were observed for circulating inflammatory biomarkers, which persisted after adjustment for confounders. These findings set the stage for validation studies and, if confirmed, biochemical pathway elucidation to inform sex-specific personalized treatment approaches.Clinical trial registered with www.clinicaltrials.gov (NCT00607893).
Authors: Reena Mehra; Fang Xu; Denise C Babineau; Russell P Tracy; Nancy S Jenny; Sanjay R Patel; Susan Redline Journal: Am J Respir Crit Care Med Date: 2010-05-27 Impact factor: 21.405
Authors: Sofien Laouafa; Alexandra Ribon-Demars; François Marcouiller; Damien Roussel; Aida Bairam; Vincent Pialoux; Vincent Joseph Journal: Sleep Date: 2017-08-01 Impact factor: 5.849
Authors: Sheila Sivam; Paul K Witting; Camilla M Hoyos; Aung M Maw; Brendon J Yee; Ronald R Grunstein; Craig L Phillips Journal: J Sleep Res Date: 2014-12-22 Impact factor: 3.981
Authors: Hassan A Chami; Ramachandran S Vasan; Martin G Larson; Emelia J Benjamin; Gary F Mitchell; Daniel J Gottlieb Journal: Sleep Med Date: 2015-11-27 Impact factor: 3.492
Authors: Clete A Kushida; Deborah A Nichols; Tyson H Holmes; Stuart F Quan; James K Walsh; Daniel J Gottlieb; Richard D Simon; Christian Guilleminault; David P White; James L Goodwin; Paula K Schweitzer; Eileen B Leary; Pamela R Hyde; Max Hirshkowitz; Sylvan Green; Linda K McEvoy; Cynthia Chan; Alan Gevins; Gary G Kay; Daniel A Bloch; Tami Crabtree; William C Dement Journal: Sleep Date: 2012-12-01 Impact factor: 5.849
Authors: MeiLan K Han; Emilio Arteaga-Solis; John Blenis; Ghada Bourjeily; Deborah J Clegg; Dawn DeMeo; Jeanne Duffy; Ben Gaston; Nicola M Heller; Anna Hemnes; Elizabeth Petri Henske; Raksha Jain; Tim Lahm; Lisa H Lancaster; Joyce Lee; Marianne J Legato; Sherry McKee; Reena Mehra; Alison Morris; Y S Prakash; Martin R Stampfli; Rashmi Gopal-Srivastava; Aaron D Laposky; Antonello Punturieri; Lora Reineck; Xenia Tigno; Janine Clayton Journal: Am J Respir Crit Care Med Date: 2018-10-01 Impact factor: 21.405